HomeQDEL • NASDAQ
add
Quidelortho Corp
Previous close
$43.58
Day range
$42.16 - $44.21
Year range
$29.74 - $84.60
Market cap
2.84B USD
Avg Volume
1.40M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Jun 2024info | Y/Y change |
|---|---|---|
Revenue | 637.00M | -4.22% |
Operating expense | 305.70M | 2.34% |
Net income | -147.70M | -177.63% |
Net profit margin | -23.19 | -189.88% |
Earnings per share | -0.07 | -126.92% |
EBITDA | 86.40M | -23.06% |
Effective tax rate | 9.33% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Jun 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 107.20M | -52.08% |
Total assets | 6.69B | -21.77% |
Total liabilities | 3.52B | -0.90% |
Total equity | 3.17B | — |
Shares outstanding | 67.24M | — |
Price to book | 0.92 | — |
Return on assets | -1.11% | — |
Return on capital | -1.25% | — |
Cash Flow
Net change in cash
| (USD) | Jun 2024info | Y/Y change |
|---|---|---|
Net income | -147.70M | -177.63% |
Cash from operations | -97.90M | -219.93% |
Cash from investing | -35.30M | 16.55% |
Cash from financing | 162.50M | 262.99% |
Net change in cash | 28.50M | 116.26% |
Free cash flow | -100.84M | -63.93% |
About
QuidelOrtho Corporation is an American manufacturer of diagnostic healthcare products that are sold worldwide.
On May 8, 2020 the U.S. Food and Drug Administration issued to Quidel the first emergency use authorization for a COVID-19 rapid antigen test, a new category of tests for use in the ongoing pandemic. These diagnostic tests quickly detect fragments of proteins found on or within the virus by testing samples collected from the nasal cavity using swabs. Wikipedia
Founded
1979
Headquarters
Website
Employees
7,100
